rethinkTHC Search
Menu
Study breakdown

Researchers created an 8-item questionnaire to screen for problematic medical cannabis use focused on negative consequences

ObservationalModerate evidence
The takeaway

A new 8-item Medicinal Cannabis Negative Consequences Scale (MCNCS) was developed and validated among 390 chronic pain patients, defining problematic medical cannabis use by its negative physiological, social, emotional, and functional consequences rather than dependence criteria.

Medical cannabis prescribers screening for problematic use; researchers studying cannabis use disorder in medical contexts.

8-item scale with 0.929 reliability distinguishes problematic from therapeutic use

What the researchers found

Starting from 36 items compiled from opioid screening tools, cannabis use disorder instruments, and patient interviews, the researchers refined to an 8-item scale with excellent internal consistency (alpha 0.929). Items focused predominantly on negative consequences rather than dependence symptoms. The scale correlated significantly with anxiety and low quality of life.

Why it matters

Existing cannabis use disorder screening tools were designed for recreational use and may overcount medical patients who show physical dependence without actual problems. This tool redefines "problematic" medical cannabis use around consequences rather than dependence criteria.

The numbers in context

390 chronic pain patients. Started with 36 items from 3 sources. Final 8-item scale. Internal consistency alpha = 0.929. Named MCNCS (Medicinal Cannabis Negative Consequences Scale). Significantly correlated with anxiety and low quality of life.

How the study worked

Scale development using 390 American chronic pain patients with medical cannabis cards. Items rated on 5-point frequency scale. Multi-group measurement invariance comparison using alcohol problems and depression as external indicators. Content validation from multiple sources.

What this study cannot tell us

Self-identified patients via online recruitment; may not represent all medical cannabis users. American sample only. Preliminary validation needs replication. No longitudinal data on whether MCNCS scores predict future adverse outcomes. Scale does not include physician assessment.

How to read the evidence

Rigorous psychometric development with appropriate validation methods, though preliminary and requires replication in diverse populations.

When this study was published

2024 study

The bigger picture

As medical cannabis expands, distinguishing therapeutic dependence from problematic use is crucial. A tool that focuses on whether cannabis use causes actual harm rather than simply flagging dependence could prevent unnecessary treatment while catching genuinely problematic patterns.

Questions still open

  • At what MCNCS score should clinicians intervene? How does this scale perform compared to standard CUD screening in medical cannabis populations?

Common questions

Why not use regular cannabis addiction screening tools?
Standard CUD tools were designed for recreational use and flag physical dependence (tolerance, withdrawal) as problematic. Medical cannabis patients may develop physical dependence as part of legitimate treatment without experiencing actual negative consequences.
What kind of negative consequences does the scale measure?
The final items covered physiological, social, emotional, and functional consequences of medical cannabis use, such as impaired daily functioning, relationship problems, and emotional disturbance, rather than dependence symptoms like tolerance.

Read the original research

Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire.

Addictive behaviors, 158, 108122

Citation

Feingold, Daniel; Gliksberg, Or; Brill, Silviu; Amit, Ben H; Lev-Ran, Shaul; Kushnir, Talma; Sznitman, Sharon R. (2024). Conceptualizing problematic use of medicinal Cannabis: Development and preliminary validation of a brief screening questionnaire.. Addictive behaviors, 158, 108122. https://doi.org/10.1016/j.addbeh.2024.108122

Explore the wider topic